The Relative Strength (RS) Rating for Centessa Pharma ADR entered a new percentile Wednesday, with an increase from 78 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains often have an RS Rating north of 80 in the early stages of their moves.
Centessa Pharma ADR is working on a cup with handle with an 18.14 buy point. See if the stock can clear the breakout price in volume at least 40% higher than normal.
Centessa Pharma ADR reported 0% earnings growth in its most recent report, while sales growth came in at -100%.
Centessa Pharma ADR earns the No. 9 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, Tempus AI and Fortrea Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
